MAP2K7 and cholangiocarcinoma: Notably, apatinib affects VEGF-mediated cell proliferation, migration, and invasion via blocking VEGFR-2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cells [49].